| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $321.5M | +244.6% |
| SG&A Expense | $50.1M | +79.8% |
| Operating Income | -$371.6M | -206.7% |
| Net Income | -$696.0M | -495.3% |
| EPS (Basic) | -$70.50 | -4047.1% |
| EPS (Diluted) | -$70.50 | -4047.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $396.5M | +383.8% |
| Short-term Investments | $58.7M | +488.6% |
| Current Assets | $458.1M | +374.7% |
| Total Assets | $464.1M | +224.8% |
| Current Liabilities | $25.2M | +35.2% |
| Total Liabilities | $628.4M | +1259.5% |
| Stockholders' Equity | -$164.3M | -270.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$142.7M | -43.2% |
| Capital Expenditures | $941K | +310.9% |
| Investing Cash Flow | -$48.8M | -150.4% |
| Financing Cash Flow | $503.8M | +843.6% |
| Free Cash Flow | -$143.7M | -43.8% |